Advertisement Pharmaceutical Business review - Page 1247 of 5293 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 9, 2026

Biohaven partners with Ono in $100m IgG degrader deal

Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with Ono Pharmaceutical for its MoDE pan immunoglobulin G (IgG) degrader portfolio.

Continue
BHV-1300 is an investigational small-molecule degrader currently under evaluation in a Phase III clinical study for Graves’ disease. Credit: SmartPhotoLab/Shutterstock.com.
October 9, 2026

Bio-Techne opens GMP small molecule facility in Bristol, UK

The Bristol site expands Bio-Techne’s manufacturing operations across the UK and the US. Credit: Quality Stock Arts/Shutterstock.com.
October 8, 2026

FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer

The regimen is indicated for adults with unresectable locally advanced or metastatic HER2+ disease following induction treatment. Credit: Arif biswas/Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. 10x Genomics and Fred Hutch partner on cancer technologies
  2. Rocket receives $150m credit facility to advance cardiovascular portfolio
  3. Gilead Sciences signs five-year DevOps agreement with Cognizant
  4. Pacira partners with Molteni for Exparel commercialisation
  5. AstraZeneca opens new R&D centre in Cambridge, US

PRESS RELEASES

Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
Pharmaceutical Business Review
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography